Sildenafil for erectile dysfunction

Drug and Therapeutics Bulletin

Volumn 36, Issue 11, 1998, Pages 81-84

[No Author Info available]

Author keywords

[No Author keywords available]

Indexed keywords

AMYL NITRATE; NITROPRUSSIDE SODIUM; ORGANIC NITRATE; PHOSPHODIESTERASE INHIBITOR; SILDENAFIL;

ADULT; AGED; ARTICLE; CLINICAL TRIAL; DRUG ABSORPTION; DRUG COST; DRUG MECHANISM; DRUG SAFETY; DYSPEPSIA; FLUSHING; HEADACHE; HUMAN; IMPOTENCE; MAJOR CLINICAL STUDY; MALE; META ANALYSIS; NOSE CONGESTION; ORAL DRUG ADMINISTRATION; PENIS ERECTION; SEXUAL BEHAVIOR; VISUAL DISORDER;

CONTROLLED CLINICAL TRIALS; HUMANS; IMPOTENCE; MALE; PHOSPHODIESTERASE INHIBITORS; PIPERAZINES;

EID: 0031766519     PISSN: 00126543     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (20)

1. Feldman HA, Goldstein I, Hatzichristou DG, Krane RJ, McKinlay JB. Impotence and its medical and psychosocial correlates: results of the Massachusetts male ageing study. J Urol 1994; 151: 54-61.
2. National Institutes of Health. Consensus development conference statement. Impotence. Int J Impot Res 1993; 5: 181-99.
3. Help for erectile impotence. DTB 1989; 27: 61-3.
4. Alprostadil for erectile impotence DTB 1995; 33: 61-2.
5. NHS Executive. Sildenafil (Viagra). Health Service Circular Department of Health, 16th September 1998; [HSC 1998/158].
6. Slag MF, Morley JE, Elson MK et al. Impotence in medical clinic outpatients. JAMA 1983; 249 1736-40.
7. O'Keefe M, Hunt DK. Assessment and treatment of impotence. Med Clin North Am 1995; 79: 415-34.
8. Kim N, Azadzoi KM, Goldstein I, Saenz de Tejada I. A nitric oxide-like factor mediates nonadrenergic-noncholinergic neurogenic relaxation of penile corpus cavernosum smooth muscle. J Clin Invest 1991, 88: 112-8.
9. Boolell M, Allen MJ, Ballard SA et al Sildenafil: an orally active type 5 cyclic GMP-spectfic phosphodiesterase inhibitor for the treatment of penile erectile dysfunction. Int J Impot Res 1996; 8: 47-52.
10. Ballard SA, Gingell CJ, Tang K, Turner LA, Price ME, Naylor AM. Effects of sildenafil on the relaxation of human corpus cavernosum tissue in vitro and on the activities of cyclic nucleotide phosphodiesterase isozymes. J Urol 1998; 159: 2164-71.
11. Sildenafil Summary of product characteristics, UK and Ireland. Pfizer Limited, September 1998.
12. Goldstein I, Lue TF, Padma-Nathan H, Rosen RC, Steers WD, Wicker PA for the Sildenafil Study Group. Oral sildenafil in the treatment of erectile dysfunction. N Engl J Med 1998; 338: 1397-404.
13. Rosen RC, Riley A, Wagner G, Osterloh IH, Kirkpatrick J, Mishra A. The International Index of Erectile Function (IIEF): a multidimensional scale for assessment of erectile dysfunction. Urology 1997; 49: 822-30.
14. Young JM and the Sildenafil Study Group. Sildenafil (Viagra) in the treatment of erectile dysfunction: a 12-week, flexible-dose study to assess efficacy and safety. Int J Impot Res 1998; 10 (suppl 3): S34 [abstract 253].
15. Price D, Wareham K, Gingell CJ, Gepi-Atte S, Pearson J, Boolell M Sildenafil (Pfizer UK-92,480), a novel oral treatment for erectile dysfunction (ED) in patients with diabetes. Diabetes 1996; 45 (suppl 2): [abstract 15].
16. Rendell MS, Moreno F. A double-blind, placebo-controlled, flexible dose-escalation study assessing the efficacy and safety of sildenafil (Viagra) in men with erectile dysfunction and diabetes. Diabetes 1998; 47 (suppl 1): A9 [abstract 0033].
17. Deny F, Glass C, Dinsmore WW et al Sildenafil (Viagra): a double-blind, placebo-controlled, single-dose, two-way crossover study in men with erectile dysfunction caused by traumatic spinal cord injury. J Neurol Sci 1997; 150 (suppl): SI34 [abstract 2-52-10].
18. Morales A, Gingell C, Collins M, Wicker PA, Osterloh IH. Clinical safety of oral sildenafil citrate (Viagra) in the treatment of erectile dysfunction. Int J Impot Res 1998; 10: 69-74.
19. Guirguis WR. The future of sex therapy in the era of oral treatment. Sex Marital Ther 1998; 13: 129-30.
20. Committee for Proprietary Medicinal Products (CPMP). European public assessment report Viagra. London: European Agency for the Evaluation of Medicinal Products, 1998.